The CALGB/SWOG 80405 (Alliance) (55) is a first line study which randomizes patients to two different drug sequences of first-line therapy for stage IV CRC: chemotherapy plus EGFR antibody (cetuximab) or chemotherapy plus VEGF antibody (bevacizumab). The gene discussed is EGFR; the disease is colorectal carcinoma.